Meclofenamic Acid Restores Gefinitib Sensitivity by Downregulating Breast Cancer Resistance Protein and Multidrug Resistance Protein 7 via FTO/m6A-Demethylation/c-Myc in Non-Small Cell Lung Cancer

BACKGROUND AND OBJECTIVE: Gefitinib (GE) is a first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for patients with advanced non-small cell lung cancer (NSCLC) carrying EGFR activating mutations. However, drug resistance limits the clinical efficacy of gefitinib and ul...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Hui, Jia, Bin, Zhang, Qiang, Zhang, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069108/
https://www.ncbi.nlm.nih.gov/pubmed/35530301
http://dx.doi.org/10.3389/fonc.2022.870636

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069108/
https://www.ncbi.nlm.nih.gov/pubmed/35530301
http://dx.doi.org/10.3389/fonc.2022.870636

Ejemplares similares